Item 2.02 Results of Operations and Financial Condition

On January 9, 2020, MacroGenics, Inc. (the "Company" or "MacroGenics") issued a press release, which included the Company's current expectations with respect to its unaudited cash, cash equivalents, and investments in marketable securities as of December 31, 2019. The press release is attached hereto as Exhibit 99.1.

The information provided under Item 2.02 in this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.




Item 8.01   Other Events

On January 9, 2020, the Company issued a press release announcing program development priorities for 2020, and indicating the upcoming availability of an updated corporate presentation on the Company's website. The press release is attached hereto as Exhibit 99.1 and incorporated by reference (other than the information that is deemed furnished in Item 2.02 above) in this Item 8.01.




Item 9.01        Financial Statements and Exhibits

(d) Exhibits.

Exhibit Number   Description of Exhibit
  99.1             Press Release, dated January 9, 2020

© Edgar Online, source Glimpses